EW-7197
|
|
|
- CAS-Nr.
- 1352608-82-2
- Englisch Name:
- EW-7197
- Synonyma:
- EW-7197;EW-7179;CPD3325;CS-2288;CS-2287;TEW-7197;NOV-1301;CPD3325-A5;Vactosertib;EW-7197 (EW7197
- CBNumber:
- CB42729651
- Summenformel:
- C22H18FN7
- Molgewicht:
- 399.42
- MOL-Datei:
- 1352608-82-2.mol
|
EW-7197 Eigenschaften
- Schmelzpunkt:
- >85oC (dec.)
- Dichte
- 1.40±0.1 g/cm3(Predicted)
- storage temp.
- Refrigerator
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 8.51±0.10(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Pale Yellow to Light Yellow
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
EW-7197 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
EW-7197 is a novel ALK-5 kinase inhibitor as well as TGF-β Type I Receptor Kinase Inhibitor. Study has shown that it can potently inhibit the breast to lung metastasis. Mice study has demonstrated that EW-7197 inhibited Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice and 4T1 orthotopic-grafted mice. EW-7197 also inhibited the epithelial-to-mesenchymal transition (EMT) in both TGFβ-treated breast cancer cells and 4T1 orthotopic-grafted mice. Furthermore, EW-7197 enhanced cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice. It can also inhibit hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling. Therefore, it is a potential antitumor reagent.
Verwenden
EW-7197 is a highly potent, selective, and orally bioavailable TGF-β I receptor ALK4/ALK5 inhibitor.
Einzelnachweise
Park, S. A., et al. "EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling." Cellular & Molecular Life Sciences 72.10(2015):2023-2039.
Kim, Min Jin, et al. "TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition." Cellular Physiology & Biochemistry International Journal of Experimental Cellular Physiology Biochemistry & Pharmacology 38.2(2016):571.
Son, J. Y., et al. "EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis." Molecular Cancer Therapeutics13.7(2014):1704.
EW-7197 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
EW-7197 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 105)Lieferanten
- EW-7197
- N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazole-2-methanamine
- NOV-1301
- TEW-7197
- N-[[4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]methyl]-2-fluoroaniline
- CPD3325-A5
- N-(2-Fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo-[1,5-a]pyridin-6-yl-1H-imidazole
- CPD3325
- 1H-Imidazole-2-methanamine, N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-
- EW-7179
- EW-7197 USP/EP/BP
- EW-7197 Vactosertib
- N-[[4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methyl-2-pyridyl)-2-imidazolyl]methyl]-2-fluoroaniline
- Vactosertib (TEW-7197)
- Vactosertib (Synonyms: EW-7197
- Vactosertib
- EW-7197;EW 7197;EW7197;TEW-7197; NOV-1301
- MK-4101 (MK 4101
- CS-2288
- EW-7197 (EW7197
- CS-2287
- Vactosertib (EW-7197
- TEW-7197EW 7197
- 1352608-82-2
- C22H18FN7
- Inhibitors
- APIs
